-
Institute of Medicine (IOM). Crossing The Quality Chasm: A New Health System For The 21st Century. IOM. 2001.
-
Alford DP, Labelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425-431.
-
Gerteis M. Through the Patient’s Eyes : Understanding and Promoting Patient-Centered Care. Vol 1st ed. San Francisco: Jossey-Bass; 1993.
-
Davis Karen, Schoenbaum Stephen C, Audet Anne-Marie. A 2020 Vision of Patient-Centered Primary Care. J Gen Intern Med. 2005;20(10):953-957. doi:10.1111/j.1525-1497.2005.0178.x.
-
Epstein Ronald M, Street Richard L. The Values and Value of Patient-Centered Care. Ann Fam Med. 2011;9(2):100-103. doi:10.1370/afm.1239.
-
Hashim MJ. Patient-Centered Communication: Basic Skills. Am Fam Physician. 2017;95(1):39-34.
-
Alves Paula CG, Sales Célia MD, Ashworth Mark. Personalising the evaluation of substance misuse treatment: a new approach to outcome measurement. Int J Drug Policy. 2015;26(4):333-335. doi:10.1016/j.drugpo.2014.11.014.
-
Bray Jeremy W, Aden Brandon, Eggman Ashley A, et al. Quality of life as an outcome of opioid use disorder treatment: A systematic review.. J Subst Abuse Treat. 2017;76:88-93. doi:10.1016/j.jsat.2017.01.019.
-
Tofighi Babak, Grossman Ellie, Buirkle Emily, McNeely Jennifer, Gourevitch Marc, Lee Joshua D. Mobile Phone Use Patterns and Preferences in Safety Net Office-Based Buprenorphine Patients.. J Addict Med. 2015;9(3):217-221. doi:10.1097/ADM.0000000000000121.
-
Renner J, Lavounis P. Handbook of Office-Based Buprenorphine Treatment of Opioid Dependence. Arlington, VA: American Psychiatric Publishing; 2011.
-
Zubkoff L, Shiner B, Watts BV. Staff Perceptions of Substance Use Disorder Treatment in VA Primary Care–Mental Health Integrated Clinics. J Subst Abuse Treat. 2016;70:44-49.
-
Sullivan L, Fiellin D. Narrative Review: Buprenorphine for Opioid-Dependent Patients in Office Practice. Ann Intern Med. 2008;148(9):662-670.
-
Drugs.com. Buprenorphine/Naloxone. 2017.
-
Blueshift Research. Camurus and Indivior Set to Significantly Sway the Opioid Abuse Treatment Market. Blueshift Research Report; 2017.
-
ASAM. Advancing access to addiction medications. 2013.
-
Szabo L. Addiction treatment hard to find, even as overdose deaths soar. USA Today. 2015.
-
Walden Greg. H.R.6 – 115th Congress (2017-2018): SUPPORT for Patients and Communities Act. October 2018.
-
Stanton A, McLoed C, Luckey B, et al. SAMHSA/CSAT Evaluation of the Buprenorphine Waiver Program. 37th Annual Medical- Scientific Conference of the American Society of Addiction Medicine. 2006.
-
SAMHSA. Substance Use Disorders. SAMHSA Website. 2014.
-
Egan JE, Casadonte P, Gartenmann T, et al. The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. J Gen Intern Med. 2010;25(9):936-941.
-
SAMHSA. Number of DATA Certified Physicians. SAMHSA.gov. 2015.
-
Addiction Treatment Forum. History of Buprenorphine. Addict Treat Forum Website. 2013.
-
CADCA. Comprehensive Addiction and Recovery Act (CARA). CADCA.org. 2016.
-
Madras BK, Wilson MC, Avula D, et al. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: Comparison at intake and six months. Drug Alcohol Depend. 2010;99(1-3):280-295.
-
SAMHSA. Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. SAMHSA.gov. 2017.
-
SAMHSA. Physician and Program Data. SAMHSA.gov. 2018.
-
ASAM. The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use. June 2015.
-
Chychula NM, Sciamanna C. Help substance abusers attain and sustain abstinence. Nurse Pract. 2002;27(11):30-47.
-
SAMHSA. Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update. Winter 2016.
-
SAMHSA. Methadone. SAMHSA.gov. 2015.
-
Office of National Drug Control Policy. Medication-Assisted Treatment for Opioid Addiction. 2012.
-
Martin J. Personal Communication Re: Number of Patients Maintained on Buprenorphine. 2011.
-
Maxwell JC, McCance-Katz EF. Indicators of buprenorphine and methadone use and abuse: what do we know?. Am J Addict. 2010;19(1):73-88.
-
Drug Enforcement Administration (DEA). Buprenorphine. 2013.
-
Sokol Randi, Albanese Chiara, Chaponis Deviney, et al. Why Use Group Visits for Opioid Use Disorder Treatment in Primary Care? A Patient-Centered Qualitative Study.. Subst Abuse. 2018;39(1):52-58. doi:10.1080/08897077.2017.1356792.
-
Roll David, Spottswood Margaret, Huang Hsiang. Using Shared Medical Appointments to Increase Access to Buprenorphine Treatment.. J Am Board Fam Med JABFM. 2015;28(5):676-677. doi:10.3122/jabfm.2015.05.150017.
-
Food and Drug Administration (FDA). Physician Information: Answers to Frequently Asked Questions. 2010.
-
SAMHSA/CSAT. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. 2004.
-
ASAM. The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use. June 2015.
-
SAMHSA. Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. SAMHSA.gov. 2017.
-
FSMB. Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office. FSMB Website. 2013.
-
National Center for Complementary and Integrative Health. NIH Analysis Shows Americans are in Pain. Natl Inst Health. 2015.
-
CDC. Opioid Data Analysis | Drug Overdose | CDC Injury Center. Cent Dis Control Prev. 2016.
-
CDC. Understanding the epidemic. Cent Dis Control Prev Natl Cent Inj Prev Control Div Unintentional Inj Prev. 2017.
-
Drug Abuse Warning Network (DAWN). Highlights of the 2011 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. The Dawn Report; 2013:127.
-
Frenk SM, Porter KS, Paulozzi LJ. Prescription opioid analgesic use among adults: United States, 1999-2012. NCHS Data Brief. 2015;189.
-
CDC. Vital Signs: Overdoses of prescription opioid pain relievers – United States, 1999-2008. MMWR. 2011;60(43):1487-1492.
-
Warner M, Hedegaard H, Chen LH. Trends in drug-poisoning deaths involving opioid analgesics and heroin: United States, 1999-2012. 2014.
-
Hedegaard H, Warner M, Minino A. Drug overdose deaths in the United States, 1999-2016. December 2017.
-
U.S. Drug Enforcement Administration (DEA), Office of Diversion Control. National Forensic Laboratory Information System: Year 2009 Annual Report. National Forensic Library Information System Annual Report; 2010.
-
Birnbaum HG, White AG, Schiller M. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;4:657-667.
-
USDHHS. Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements. 2016.
-
Savage SD, Kirsh KL, Passik SD. Challenges in using opioids to treat pain in persons with substance use disorders. Addict Sci Clin Pract. 2008;4(2):4-25.
-
Passik S. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006;20(2):5-13.
-
SAMHSA. Substance Use Disorders. SAMHSA Website. 2014.
-
Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. MMWR Recomm Rep. 2016;65(1):1-49. doi:10.15585/mmwr.rr6501e1er.
-
Edlund MJ, Martin BC, Russo JE, et al. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain. 2014;30(7):557-564.
-
American Psychiatric Association. Substance-Related and Addictive Disorders. APA. 2013.
-
Jones CM, Logan J, Gladden M, et al. Vital signs: Demographic and substance use trends among heroin users — United States, 2002-2013. CDC Morb Mortal Wkly Rep. 2015;64(26):719-725.
-
Center for Behavioral Health Statistics and Quality. Key Substance Use and Mental Health Indicators in the United States: Results from the 2015 National Survey on Drug Use and Health. 2016.
-
Chou Roger, Fanciullo Gilbert J, Fine Perry G, et al. Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. J Pain Off J Am Pain Soc. 2009;10(2):113-130. doi:10.1016/j.jpain.2008.10.008.
-
Back SE, Payne RL, Simpson AN. Gender and prescription opioids: findings from the National Survey on Drug Use and Health. Addict Behav. 2010;35:1001-1007.
-
U.S. Department of Health and Human Services. Addressing prescription drug abuse in the United States. 2013.
-
Vivolo-Kantor Alana M. Vital Signs: Trends in Emergency Department Visits for Suspected Opioid Overdoses — United States, July 2016–September 2017. MMWR Morb Mortal Wkly Rep. 2018;67. doi:10.15585/mmwr.mm6709e1.
-
Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2012 national survey on drug use and health: summary of national findings. U.S. Department of Health and Human Services; 2013.
-
Paulozzi LJ, Baldwin G. CDC Grand Rounds: Prescription Drug Overdoses — a U.S. Epidemic. CDC Morb Mortal Wkly Rep. 2012;61(01):10-13.
-
Rudd Rose A. Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65. doi:10.15585/mmwr.mm655051e1.
-
Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. 2009.
-
CDC. Prescription Drug Overdose Data. 2015.
-
Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85-92.
-
Washington State Agency Medical Directors’ Group (AMDG). Interagency Guideline on Prescribing Opioids for Pai. June 2015.
-
FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. US Food Drug Adm Cent Drug Eval Res. August 2016.
-
FDA. New, Safety Measures Announced for Extended-release and Long-acting Opioids. FDA Website. 2013.
-
Vivus, Inc. Highlights of Prescribing Information. FDA.org. 2014.
-
Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. Am J Drug Alcohol Abuse. 2011;37(1):1-11.
-
Martins SS, Keyes KM, Storr CL. Pathways between non-medical opioid use/dependence and psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2009;103:16-24.
-
Seal KH, Shi Y, Cohen G. Association of Mental Health Disorders With Prescription Opioids and High-Risk Opioid Use in US Veterans of Iraq and Afghanistan. JAMA. 2012;307:940-947.
-
Kraus ML, Alford DP, Kotz MM, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction. J Addict Med. 2011;5(4):254-263.
-
Brady KT, Myrick H, Sonne S. Comorbid addiction and affective disorders. In: In: Graham AW, Schultz TK, Eds. Principles of Addiction Medicine. Vol Second Edition. Chevy Chase, Md: American Society of Addiction Medicine; 1998.
-
Fishman MJ, Wu LT, Woody GE. Buprenorphine for Prescription Opioid Addiction in a Patient With Depression and Alcohol Dependence. Am J Psychiatry. 2011;168(7):675-679.
-
Pani PP, Vacca R, Troqu E, et al. Pharmacological treatment for depression during opioid agonist treatment for opioid dependence. Cochrane Database Syst Rev. 2010;8(9):CD008373.
-
USPSTF. Draft Update Summary: Unhealthy Alcohol Use in Adolescents and Adults, Including Pregnant Women: Screening and Behavioral Counseling Interventions – US Preventive Services Task Force. August 2016.
-
Trémeau F, Darreye A, Staner L, et al. Suicidality in opioid-dependent subjects. Am J Addict. 2008;17(3):187-194.
-
Darke S, Ross J. Suicide among heroin users: rates, risk factors and methods. Addiction. 2002;97(11):1383-1394.
-
Hubbard RL, Craddock SG, Anderson J. Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). 2003.
-
SAMHSA. Use of Buprenorphine in the Pharmacologic Management of Opioid Dependence: A Curriculum for Physicians. 2001.
-
FDA. Medication Guide: ButransTM CIII (buprenorphine) Transdermal System. 2010.
-
Papastavrou E, Farmakas A, Karayiannis G, et al. Co morbidity of Post-Traumatic-Stress Disorders and Substance Use Disorder. Health Science Journal. Health Sci J. 2011;5(2):107-117.
-
Verheul R. Co-morbidity of personality disorders in individuals with substance use disorders. Eur Psychiatry. 2001;16(5):274-282.
-
Sansone RA, Whitecar P, Wiederman MW. The prevalence of borderline personality among buprenorphine patients. Int J Psychiatry Med. 2008;38(2):217-226.
-
Kidorf M, Disney ER, King VL, et al. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug Alcohol Depend. 2004;74(2):115-122.
-
Renner J, Saxon A, Levounis P. Buprenorphine Update and Evolving Standards of Care. IPS: The Mental Health Services Conference. October 2015. New York City.
-
Moos RH, Moos BS, Finney JW. Predictors of deterioration among patients with substance-use disorders. J Clin Psychol. 2001;57(12):1403-1419.
-
Hesse M. The ASRS-6 Has Two Latent Factors: Attention Deficit and Hyperactivity. J Atten Disord. 2011;17(3):203-207.
-
Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. Neonatal ICUs. NEJM. 2015;372:2118-2126.
-
Cicero JT, Dart RC, Inciardi JA, et al. The Development of a Comprehensive Risk-Management Program for Prescription Opioid Analgesics: Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS). Pain Med. 2007;8(2):157-169.
-
Dart RC. Opioid Abuse, Misuse, and Diversion: Strategies for Prevention. Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS). American Academy of Pain Medicine Meeting. 2009.
-
National Institute on Drug Abuse. Linked Epidemics: Drug Abuse and HIV/AIDS. 2005.
-
Rondinelli AJ, Ouellet LJ, Strathdee A, et al. Young adult injection drug users in the United States continue to practice HIV risk behaviors. Drug Alcohol Depend. 2009;104(1-2):167-174.
-
Neaigus A, Miller M, Gyarmathy VA, et al. HIV heterosexual sexual risk from injecting drug users among HIV-seronegative noninjecting heroin users. Subst Use Misuse. 2011;46(2-3):208-217.
-
Jung O, Haack HS, Buettner M. Renal AA-amyloidosis in intravenous drug users – a role for HIV-infection?. BMC Nephrol. 2012;13.
-
Bruce RD. Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. Int J Drug Policy. 2010;21:122-124.
-
Stanton A, McLoed C, Luckey B, et al. SAMHSA/CSAT Evaluation of the Buprenorphine Waiver Program. 37th Annual Medical- Scientific Conference of the American Society of Addiction Medicine. 2006.
-
Monto A, Currie S, Wright TL. Liver disease in injection drug users with hepatitis C, with and without HIV coinfection. J Addict Dis. 2008;27(2):49-59.
-
Gyarmathy VA, Neaigus A, Miller M, et al. Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users. J Acquir Immune Defic Syndr. 2002;30(4):448-456.
-
Lange CM, Jacobson IM, Rice CM. Emerging therapies for the treatment of hepatitis C. EMBO Mol Med. 2014;6:4-15.
-
Hagan H, Pouget ER, Des Jarlais DC. A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs. J Infect Dis. 2011;204:74-83.
-
Perneger TV, Klag MJ, Whelton PK. Recreational drug use: a neglected risk factor for end-stage renal disease. Am J Kidney Dis. 2001;38(1):49-56.
-
Schoener EP, Hopper JA, Pierre JD. Injection drug use in North America. Infect Dis Clin North Am. 2002;16(3):535-551.
-
Degenhardt L, Bucello C, Mathers B. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106:32-51.
-
Harned M, Sloan P. Safety concerns with long-term opioid use. Expert Opin Drug Saf. 2016;15(7):955-962.
-
Manubay JM, Muchow C, Sullivan MA. Prescription drug abuse: epidemiology, regulatory issues, chronic pain management with narcotic analgesics. Prim Care. 2011;38(1):71-90, vi.
-
SAMHSA/CSAT. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. 2004.
-
SAMHSA. Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update. Winter 2016.
-
FSMB. Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office. FSMB Website. 2013.
-
U.S. Preventive Services Task Force. Screening for Illicit Drug Use. 2008.
-
NIDA. Screening for drug use in general medical settings. http://www.drugabuse.gov/. 2012.
-
Walden Greg. Text – H.R.6 – 115th Congress (2017-2018): SUPPORT for Patients and Communities Act. October 2018.
-
American Psychiatric Association. Substance-Related and Addictive Disorders. APA. 2013.
-
Zacny J, Bigelow G, Compton P, et al. College on Problems of Drug Dependence task force on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend. 2003;69(3):215-232.
-
Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy for chronic non-cancer pain. J of Pain. 2009;10(2):113-130.
-
Smith PC, Schmidt SM, Allensworth-Davies D, et al. A single-question screening test for drug use in primary care. Arch Intern Med. 2010;170(13):1155-1160.
-
UMBCtube. SBIRT: Screen for Substance Use – Negative Screen. UMBCtube; 2011.
-
Mdege ND, Lang J. Screening instruments for detecting illicit drug use abuse that could be useful in general hospital wards: a systematic review. Addict Behav. 2011;36:1111-1119.
-
Brown RL, Leonard T, Saunders LA, et al. The prevalence and detection of substance use disorder among inpatients ages 18 to 49: an opportunity for prevention. Prev Med. 1998;27:101-110.
-
Babor TF, Higgins-Biddle JC, Saunders JB, et al. AUDIT: The Alcohol Use Disorders Identification Test Guidelines for Use in Primary Care. Vol Second edition. World Health Organization, Department of Mental Health and Substance Dependence; 2001.
-
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Vol 5th edition. Washington, DC: Author; 2013.
-
Trachtenberg AI, Fleming MF. Diagnosis and Treatment of Drug Abuse in Family Practice. 1994.
-
Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989;84(11):1353-1357.
-
Miller William R, Rollnick Stephen. Motivational Interviewing: Helping People Change, 3rd Edition. Vol 3rd edition. New York, NY: The Guilford Press; 2012.
-
Lundahl B, Moleni T, Burke BL, et al. Motivational interviewing in medical care settings: a systematic review and meta-analysis of randomized controlled trials. 93. 2013;2:157-168.
-
Miller WR, Rollnick S. An Overview of Motivational Interviewing. 2011.
-
Magill M, Stout RL, Apodaca TR. Therapist focus on ambivalence and commitment: a longitudinal analysis of motivational interviewing treatment ingredients. Psychol Addict Behav. 2013;27:754-762.
-
Clinical Tools, Inc. Motivational Interviewing: Managing Challenging Patient Behavior. Chapel Hill, NC: Clinical Tools, Inc.; 2016.
-
Kaul P, Coupey SM. Clinical evaluation of substance abuse. Pediatr Rev. 2002;23(3):85-94.
-
Kraus ML, Alford DP, Kotz MM, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction. J Addict Med. 2011;5(4):254-263.
-
Schulz JE, Parran T Jr. Principles of Identification and Intervention. In: Principles of Addiction Medicine. Vol 2nd ed. Chevy Chase, Md.: American Society of Addiction Medicine; 1998:250-251.
-
SAMHSA. Use of Buprenorphine in the Pharmacologic Management of Opioid Dependence: A Curriculum for Physicians. 2001.
-
Pickett M, Rogers PD, Cavanaugh Jr RM. Screening for alcohol, tobacco, and drug use in children and adolescents. In: In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine. Vol Third Edition. Chevy Chase, Md: American Society of Addiction Medicine; 2003.
-
American Academy of Pediatrics. Alcohol use by youth and adolescents: a pediatric concern. Pediatrics. 2010;125(5):1078-1087.
-
Knight JR, Shrier LA, Bravender TD, et al. A new brief screen for adolescent substance abuse. Arch Pediatr Adolesc Med. 1999;153(6):591-596.
-
Marshal Michael P, Molina Brooke SG, Pelham William E. Childhood ADHD and Adolescent Substance Use: An Examination of Deviant Peer Group Affiliation as a Risk Factor. Psychol Addict Behav J Soc Psychol Addict Behav. 2003;17(4):293-302. doi:10.1037/0893-164X.17.4.293.
-
Al-Tayyib A, Rice E, Rhoades H, et al. Association between prescription drug misuse and injection among runaway homeless youth. Drug Alcohol Depend. 2013;134:406-409.
-
Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT). A Guide to Substance Abuse Services for Primary Care Clinicians. Rockville, Md: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration; 2008.
-
Tamm L, Trello-Rishel K, Riggs P, et al. Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder. Subst Abuse Treat. 2013;44(2):224-230.
-
Warden Diane, Riggs Paula D, Min Sung-Joon, et al. Major depression and treatment response in adolescents with ADHD and substance use disorder. Drug Alcohol Depend. 2011;120(1-3):214-219.
-
Cirone S. Brief Intervention: Adolescent with Prescription Opioid Use Disorder. ; 2013.
-
SAMHSA/CSAT. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. 2004.
-
ASAM. The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use. June 2015.
-
SAMHSA. Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update. Winter 2016.
-
FSMB. Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office. FSMB Website. 2013.
-
USDHHS. Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements. 2016.
-
Farmer Carrie M, Lindsay Dawn, Williams Jessica, et al. Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process. Subst Abuse. 2015;36(2):209-216. doi:10.1080/08897077.2015.1012613.
-
SAMHSA. Screening, Brief Intervention, and Referral to Treatment (SBIRT). 2014.
-
Hale D, Viner R. Trends in the prevalence of multiple substance use in adolescents in England, 1998-2009. J of Public Health, Oxford. 2013;35(3):367-374.
-
Farmer CM, Lindsay D, Williams J, et al. Practice Guidelines for Burprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process. 2015;36(2).
-
Strain EC. Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin J Pain. 2002;18(4 Suppl)(S14-27).
-
Kidorf M, Disney ER, King VL, et al. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug Alcohol Depend. 2004;74(2):115-122.
-
UMBCtube. SBIRT: Screen for Substance Use – Negative Screen. UMBCtube; 2011.
-
FDA. CLIA – Clinical laboratory improvement amendments – currently waived analytes. 2016.
-
Richert Torkel, Johnson Björn. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden. Harm Reduct J. 2015;12. doi:10.1186/s12954-015-0037-2.
-
Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders Stabilization Pocket Card. 2015.
-
Sullivan MA, Covey LS. Current perspectives on smoking cessation among substance abusers. Curr Psychiatry Rep. 2002;4(5):388-396.
-
Kalman D, Morissette SB, George TP. Co-Morbidity of Smoking in Patients with Psychiatric and Substance Use Disorders. Am J Addict. 2005;14(2):106-123.
-
SAMHSA. Tobacco Use Cessation During Substance Abuse Treatment Counseling. SAMHSA Advis. 2011;10(2):1-8.
-
Sees KL, Clark HW. When to begin smoking cessation in substance abusers. J Subst Abuse Treat. 1993;10(2):189-195.
-
Reid MS, Mickalian JD, Delucchi KL, et al. An acute dose of nicotine enhances cue-induced cocaine craving. Drug Alcohol Depend. 1998;49(2):95-104.
-
Pajusco B, Chiamulera C, Quaglio G, et al. Tobacco Addiction and Smoking Status in Heroin Addicts under Methadone vs. Buprenorphine Therapy. Int J Environ Res Public Health. 2012;9(3):932-942.
-
Baca CT, Yahne CE. Smoking cessation during substance abuse treatment: what you need to know. J Subst Abuse Treat. 2009;36(2):205-219.
-
Reid MS, Selzer J, Rotrosen J. Smoking Cessation treatment at Substance Abuse Rehabilitation Programs. Northeast ATTC Newsl. 2006;5(2):2-5.
-
Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J Consult Clin Psychol. 2004;76(6):1144-1156.
-
Shoptaw S, Rotheram-Fuller E, Yang X, et al. Smoking cessation in methadone maintenance. Addiction. 2002;97(10):1317-1328.
-
Lemon SC, Friedmann PD, Stein MD. The impact of smoking cessation on drug abuse treatment outcome. Addict Behav. 2003;28(7):1323-1331.
-
Joseph AM, Willenbring ML, Nugent SM, et al. A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. J Stud Alcohol. 2004;65(6):681-691.
-
Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2008.
-
Klimas Jan, Field Catherine-Anne, Cullen Walter, et al. Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users: Cochrane Review. Syst Rev. 2013;2.
-
Gudin JA, Mogali S, Jones JD. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. Postgrad Med. 2013;125(4):115-130.
-
Sterling S, Chi F, Hinman A. Integrating Care for People With Co-Occurring Alcohol and Other Drug, Medical, and Mental Health Conditions. Alcohol Res Health. 2011;33(4):338-349.
-
FDA. Medication Guide: Zubsolv Sublingual Tablet (CIII). July 2013.
-
Kraus ML, Alford DP, Kotz MM, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction. J Addict Med. 2011;5(4):254-263.
-
Brands B, Blake J, Sproule B, et al. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend. 2004;73(2):199-207.
-
Moore BA, Fiellin DA, Barry DT, et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med. 2007;22:527-530.
-
Nielsen S, Hillhouse M, Thomas C. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. J Addict Med. 2013;7(1):33-38.
-
Potter JS, Marino EN, Hillhouse MP. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs. 2013;74(4):605-613.
-
Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. ; 2014.
-
Leger DL. Study: heroin use is higher than a decade ago. USA Today. 2015.
-
Eggleston W, Clark KH, Marraffa JM. Loperamide abuse associated with cardiac dysrhythmia and death. Ann Emerg Med. 2016. doi:http://dx.doi.org/10.1016/j.annemergmed.2016.03.047.
-
Kleber H, Weiss R, Anton R, et al. Practice guideline for the treatment of patients with substance use disorders. Vol 3rd edition. American Psychiatric Association; 2010.
-
Renner J, Saxon A, Levounis P. Buprenorphine Update and Evolving Standards of Care. IPS: The Mental Health Services Conference. October 2015. New York City.
-
Harned M, Sloan P. Safety concerns with long-term opioid use. Expert Opin Drug Saf. 2016;15(7):955-962.
-
Marshall PS. Physical Functional Ability Questionnaire (FAQ5). In: In: Assessment and Management of Chronic Pain. Vol 14. 5th edition. Institute for Clinical Systems Improvement; 2011:Appendix C:99.
-
Erdemoglu AK, Koc R. Brief Pain Inventory score identifying and discriminating neuropathic and nociceptive pain. Acta Neurol Scand. 2013;128(5):351-358.
-
Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9(4):444-459.
-
Wu LT, Woody GE, Yang C, et al. Subtypes of nonmedical opioid users: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2010;112:69-80.
-
USPSTF. Draft Update Summary: Unhealthy Alcohol Use in Adolescents and Adults, Including Pregnant Women: Screening and Behavioral Counseling Interventions – US Preventive Services Task Force. August 2016.
-
Hasin D, Liu XH, Nunes E, et al. Effects of major depression on remission and relapse of substance dependence. Arch Gen Psychiatry. 2002;59:375-380.
-
Fishman MJ, Wu LT, Woody GE. Buprenorphine for Prescription Opioid Addiction in a Patient With Depression and Alcohol Dependence. Am J Psychiatry. 2011;168(7):675-679.
-
Fiellin DA, Rosenheck RA, Kosten TR. Office-based treatment for opioid dependence: reaching new patient populations. Am J Psychiatry. 2001;158(8):1200-1204.
-
Mee-Lee D. The ASAM Criteria. Vol 3rd edition. ASAM; 2013.
-
McClellan AT, McKay JR. Components of successful addiction treatment. In: N: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine. Vol Third Edition. Chevy Chase, Md: American Society of Addiction Medicine; 2003:3.
-
Stine SM, Greenwald MK, Kosten TR. Pharmacologic interventions for opioid addiction. In: In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine. Vol Third Edition. Chevy Chase, Md; 2003.
-
Fishman MJ, Mee-Lee D, Schulman GD, et al. Supplement to the ASAM Patient Placement Criteria on the Management of Alcohol Use Disorders. Baltimore, MD: Lippincott, Williams & Wilkins, Inc; 2010.
-
VA/DoD. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. VA/DoD. 2015.
-
Jones HE, Fischer G, Heil SH. Maternal Opioid Treatment: Human Experimental Research (MOTHER) – approach, issues and lessons learned. Addiction. 2012;107:28-35.
-
Hopfer CJ, Khuri E, Crowley TJ, et al. Adolescent heroin use: a review of the descriptive and treatment literature. J Subst Abuse Treat. 2002;23(3):231-237.
-
SAMHSA. Treatment of Adolescents With Substance Use Disorders. Treatment Improvement Protocol Series, No. 32. Rockville, Md: Center For Substance Abuse Treatment; 1999.
-
Conigliaro J, Reyes CD, Parran TV, et al. Principles of screening and early intervention. In: In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine. Vol Third Edition. Chevy Chase, Md: American Society of Addiction Medicine; 2003.
-
CADCA. Comprehensive Addiction and Recovery Act (CARA). CADCA.org. 2016.
-
Madras BK, Wilson MC, Avula D, et al. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: Comparison at intake and six months. Drug Alcohol Depend. 2010;99(1-3):280-295.
-
SAMHSA/CSAT. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. 2004.
-
SAMHSA. Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update. Winter 2016.
-
FSMB. Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office. FSMB Website. 2013.
-
De Vries TJ, Shippenberg TS. Neural systems underlying opiate addiction. J Neurosci. 2002;22(9):3321-3325.
-
Borg L, Kreek MJ. The pharmacology of opioids. In: In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine. Vol 3. 3rd ed. Chevy Chase, Md: American Society of Addiction Medicine; 2003.
-
Xi ZX, Stein EA. GABAergic mechanisms of opiate reinforcement. Alcohol Alcohol. 2002;37(5):485-494.
-
Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5):627-632.
-
American Psychiatric Association. Substance-Related and Addictive Disorders. APA. 2013.
-
Kosten TR, George TP. The neurobiology of opioid addiction: implications for treatment. NIDA Sci Pract Perspect. 2002;1(1):13-20.
-
Henry JA. Metabolic consequences of drug misuse. Br J Anaesth. 2000;85(1):136-142.
-
Volkow N. NIDA-supported science leads to first FDA-approved medication for opioid withdrawal. NIDA. 2018.
-
FDA. FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults. 2018.
-
National Drug Intelligence Center (NDIC). Intelligence Bulletin: Buprenorphine: Potential for Abuse. 2004.
-
SAMHSA. Protracted withdrawal. SAMHSA Advis. 2010;9(1).
-
21 USC § 812. Schedules of controlled substances. 2012.
-
Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003;70(suppl 2):S59-S77.
-
FDA. Medication Guide: ButransTM CIII (buprenorphine) Transdermal System. 2010.
-
Labelle CT, Han SC, Bergeron A, et al. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers. J Subst Abuse Treat. 2015;15.
-
Kraus ML, Alford DP, Kotz MM, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction. J Addict Med. 2011;5(4):254-263.
-
BioDelivery Sciences International. Bunavail prescribing information. 2014.
-
Stanton A, McLoed C, Luckey B, et al. SAMHSA/CSAT Evaluation of the Buprenorphine Waiver Program. 37th Annual Medical- Scientific Conference of the American Society of Addiction Medicine. 2006.
-
Walsh SL. Clinically Relevant Pharmacology of Buprenorphine. 2009.
-
Huestis MA. High-dose buprenorphine in humans. In: In: Kintz P, Marquet P, Eds. Buprenorphine Therapy of Opiate Addiction. Vol Totowa, NJ: Humana Press, Inc; 2002.
-
Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70(suppl 2):S39-S47.
-
Tzschentke Thomas M. Behavioral Pharmacology of Buprenorphine, with a Focus on Preclinical Models of Reward and Addiction. Psychopharmacology (Berl). 2002;161(1):1-16. doi:10.1007/s00213-002-1003-8.
-
Donaher PA, Welsh C. Managing opioid addiction with buprenorphine. Am Fam Physician. 2006;73(9):1573-1578.
-
SAMHSA. Substance Use Disorders. SAMHSA Website. 2014.
-
Kahan M, Srivastava A, Ordean A, et al. Buprenorphine: new treatment of opioid addiction in primary care. Can Fam Physician. 2011;57(3):281-289.
-
Yokell MA, Zaller ND, Green TC, et al. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011;4:28-41.
-
Durand F, Valla D. Assessment of prognosis of cirrhosis. Clin Pharmacokinet. 2008;28(1):110-122.
-
Nasser AF, Heidbreder C, Liu Y, et al. Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment (Child-Pugh classes A, B, and C), in hepatitis C virus-seropositive subjects, and in healthy volunteers. Clin Pharmacokinet. 2015;54(8):837-849.
-
Roxane Laboratories. Buprenorphine and naloxone sublingual tablets: Full prescribing information. DailyMed. 2016.
-
Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?. Drug Alcohol Depend. 2003;70(2S):S29-S37.
-
Renner J, Saxon A, Levounis P. Buprenorphine Update and Evolving Standards of Care. IPS: The Mental Health Services Conference. October 2015. New York City.
-
Kissin W, McLeod C, Sonnefeld J, et al. Experiences of a National Sample of Qualified Addiction Specialists Who Have and Have Not Prescribed Buprenorphine for Opioid Dependence. J Addict Dis. 2006;25(4):91-103.
-
Alford DP, Labelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425-431.
-
Arfken CL, Johanson CE, di Menza S, et al. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. J Subst Abuse Treat. 2010;39(2):96-104.
-
Mintzer IL, Eisenberg M, Terra M, et al. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med. 2007;5(2):146-150.
-
FDA. FDA approves first buprenorphine implant for treatment of opioid dependence. FDA News Events. May 2016.
-
FDA. FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder. November 2017.
-
Reckitt Benckiser Pharmaceuticals Inc. Suboxone Prescribing Information. 2014.
-
Farney RJ, McDonald AM, Boyle KM, et al. Sleep disordered breathing in patients receiving therapy with buprenorphine/naloxone. Eur Respir. 2013;42:394-403.
-
Lintzeris N, Clark N, Muhleisen P, et al. National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Treatment of Heroin Dependence. 2001.
-
Weiss RD, Potter JS, Fiellin DA. Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence. Arch Gen Psychiatry. 2012;68(12):1238-1246.
-
Fiellin DA, Schottenfeld RS, Cutter CJ, et al. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial. JAMA Intern Med. 2014;174(12):1947-1954.
-
Dunn KE, Sigmon SC, Strain EC. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. Drug Alcohol Depend. 2011;119(1-2):1-9.
-
Kao Ming-Chih, Zheng Patricia, Mackey Sean, et al. Trends in Benzodiazepine Prescription and Co-Prescription with Opioids in the United States, 2002––2009. AAPM Annual Meeting. July 2014.
-
Maxwell JC, McCance-Katz EF. Indicators of buprenorphine and methadone use and abuse: what do we know?. Am J Addict. 2010;19(1):73-88.
-
ASAM. The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use. June 2015.
-
Stein DJ, Isper JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2006;1:CD002795.
-
Taylor FB, Martin P, Thompson C, et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: A placebo-controlled study. Biol Psychiatry. 2008;63(6):629-632.
-
Drugs.com. Doxazosin. Drugs.com. November 2015.
-
McNicholas LF. Buprenorphine: Induction, Dosing and Related Issues. American Psychiatric Association Sponsored Webinar; 2011.
-
Food and Drug Administration (FDA). Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) Risk Evaluation and Mitigation Strategy (REMS). 2013.
-
NIAAA. Alcohol Facts and Statistics. NIAAA. 2015.
-
Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. Am J Drug Alcohol Abuse. 2011;37(1):1-11.
-
Guo AY, Ma JD, Best BM, et al. Urine specimen detection of concurrent nonprescribed medicinal and illicit drug use in patients prescribed buprenorphine. J Anal Toxicol. 2013;37(9):636-641.
-
NIH. National Trends. 2014.
-
APA. Focus on Marijuana: Current Risks and Controversies. Am Psychiatr Assoc Webinar. 2012.
-
McCance-Katz EF. Treatment of Opioid Dependence and Coinfection with HIV and Hepatitis C Virus in Opioid-Dependent Patients: The Importance of Drug Interactions between Opioids and Antiretroviral Agents. Clin Infect Dis. 2005;41(suppl 1):S89-95.
-
Gruber VA, McCance-Katz EF. Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr HIV/AIDS Rep. 2010;7(3):156-160.
-
McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend. 2007;91(2-3):269-278.
-
Saxon AJ, Ling W, Hillhouse M, et al. Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: A randomized trial. Drug Alcohol Depend. 2013;128:71-76.
-
Herve S, Riachi G, Noblet C, et al. Acute hepatitis due to buprenorphine administration. Eur J Gastroenterol Hepatol. 2004;16(10):1033-1037.
-
ASAM. Summary of the Comprehensive Addiction and Recovery Act. 2016.
-
SAMHSA. Methadone. SAMHSA.gov. 2015.
-
Mattick RP, Breen C, Kimber J. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Libr. 2014.
-
Office of National Drug Control Policy. Medication-Assisted Treatment for Opioid Addiction. 2012.
-
Lee JD, Friedmann PD, Kinlock TW, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374:1232-1242.
-
PCSS. Vivitrol: How important is this piece of the treatment puzzle?. 2015.
-
PCSS. XR-Naltrexone: A step-by-step guide. 2017.
-
Substance Abuse and Mental Health Services Administration (US), Office of the Surgeon General (US). Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health. Washington (DC): US Department of Health and Human Services; 2016.
-
SAMHSA. Decisions in Recovery. Treatment for Opioid Use Disorder.. 2017.
-
SAMHSA/CSAT. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. 2004.
-
SAMHSA. Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update. Winter 2016.
-
FSMB. Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office. FSMB Website. 2013.
-
Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70(suppl 2):S39-S47.
-
Nasser AF, Heidbreder C, Liu Y, et al. Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment (Child-Pugh classes A, B, and C), in hepatitis C virus-seropositive subjects, and in healthy volunteers. Clin Pharmacokinet. 2015;54(8):837-849.
-
Fudin J. A Brief Review of Buprenorphine Products. March 2016.
-
Breen C. There’s a New Buprenorphine on the Block | Dr. Jeffrey Fudin. PainDr. February 2018.
-
Strain EC, Moody DE, Stoller KE, et al. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend. 2004;74(1):37-43.
-
Yokell MA, Zaller ND, Green TC, et al. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011;4:28-41.
-
Ling W, Casadonte P, Bigelow G. Buprenorphine Implants for Treatment of Opioid Dependence. JAMA. 2010;304(14):1576-1583.
-
Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003;70(suppl 2):S59-S77.
-
Larance B, Lintzeris N, Dietze P, et al. The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug Alcohol Depend. 2014;136:21-27.
-
Orexo US Inc. Zubsolv prescribing information. 2013.
-
Rx List. Suboxone. Rx List Website. 2014.
-
BioDelivery Sciences International. Bunavail prescribing information. 2014.
-
Sontag D. Addiction Treatment With a Dark Side. N Y Times. 2013.
-
ASAM. The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use. June 2015.
-
Dart R. Evaluation of ADFs Using RADARS System Data. 2011.
-
Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007;88(1):75-78.
-
FDA. FDA approves first buprenorphine implant for treatment of opioid dependence. FDA News Events. May 2016.
-
Chen MC, Beebe K. A randomized trial of Probuphine implants in adults stabilized on sublingual buprenorphine. American Society of Addiction Medicine (ASAM) Annual Meeting. 2016.
-
Rosenthal RN, Lofwall MR, Kim S, et al. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine. A randomized clinical trial. JAMA. 2016;316:282-290.
-
FDA. FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder. November 2017.
-
Sublocade. Medication Guide Sublocade (buprenorphine extended-release) injection, for subcutaneous use (CIII). November 2017.
-
Medscape. Sublocade (buprenorphine, long-acting injection) dosing, indications, interactions, adverse effects, and more. 2018.
-
American Society of Health-System Pharmacists. Buprenorphine Injection: MedlinePlus Drug Information. April 2018.
-
Reckitt Benckiser Pharmaceuticals Inc. Buprenex injectable – RX only – Schedule III. 2007.
-
Belbuca. Belbuca HPC important safety information. www.belbuca.com. 2015.
-
Purdue Pharma. ButransTM CIII (buprenorphine) Transdermal System. Butrans Website. 2010.
-
Sullivan MA, Gordon AJ. MAT training: Provider’s clinical support system for medication assisted treatment. 2013.
-
SAMHSA/CSAT. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. 2004.
-
SAMHSA. Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update. Winter 2016.
-
FSMB. Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office. FSMB Website. 2013.
-
Gunderson E. Models of Buprenorphine Induction. PCSSMAT Train. 2014.
-
Indivior Inc. Suboxone Highlights of Prescribing Information. http://www.suboxone.com/. December 2016.
-
McNicholas LF. Buprenorphine: Induction, Dosing and Related Issues. American Psychiatric Association Sponsored Webinar; 2011.
-
Kraus ML, Alford DP, Kotz MM, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction. J Addict Med. 2011;5(4):254-263.
-
Food and Drug Administration (FDA). Appropriate Use Checklist. http://btodrems.com/. 2013.
-
American Psychiatric Association. Substance-Related and Addictive Disorders. APA. 2013.
-
Labelle CT, Han SC, Bergeron A, et al. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers. J Subst Abuse Treat. 2015;15.
-
Orexo US Inc. Zubsolv prescribing information. 2013.
-
Alford DP, Labelle CT, Richardson JM, et al. Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-Based Setting. Soc Gen Intern Med. 2007;22:171-176.
-
Lee JD, Grossman E, DiRocco D, et al. Home Buprenorphine/Naloxone Induction in Primary Care. J Gen Intern Med. 2009;24(2):226-232.
-
ASAM. The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use. June 2015.
-
Casadonte PP. PCSS Guidance: Buprenorphine Induction. Physician Clin Support Syst Website. 2009.
-
Bliesener N, Albrecht S, Schwager A, et al. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2005;90(1):203.
-
Mannelli P, Peindl KS, Lee T. Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. Curr Drug Abuse Rev. 2012;5(1):52-63.
-
Glasper A, Reed LJ, de Wet CJ, et al. Induction of patients with moderately severe methadone dependence onto buprenorphine. Addict Biol. 2005;10(2):149-155.
-
Johanson CE, Arfken CL, DiMenza S, et al. Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians. Drug Alcohol Depend. 2012;120(1-3):190-195.
-
Lofwall MR, Havens JR. Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. Drug Alcohol Depen. 2012;Jun 13 [Epub ahead of print].
-
Wish ED, Artigiani D, Billing A, et al. The emerging buprenorphine epidemic in the United States. J Addict Dis. 2012;31(1):3-7.
-
Oreskovich MR, Saxon AJ, Ellis ML, et al. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin. Drug Alcohol Depend. 2005;77(1):71-79.
-
Amass L, Ling W, Freese TE, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict. 2004;13:Suppl 1: S42-66.
-
Kosten TR, George TP. The neurobiology of opioid addiction: implications for treatment. NIDA Sci Pract Perspect. 2002;1(1):13-20.
-
Kakko J, Svanborg KD, Kreek MJ, et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662-668.
-
Farmer Carrie M, Lindsay Dawn, Williams Jessica, et al. Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process. Subst Abuse. 2015;36(2):209-216. doi:10.1080/08897077.2015.1012613.
-
Lintzeris N, Clark N, Muhleisen P, et al. National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Treatment of Heroin Dependence. 2001.
-
Weiss RD, Potter JS, Griffin ML, et al. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. Drug Alcohol Depend. 2015.
-
Ling W, Hillhouse M, Domier C, et al. Buprenorphine tapering schedule and illicit opioid use. Addiction. 2009;104(2):256-265.
-
SAMHSA. Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update. Winter 2016.
-
SAMHSA/CSAT. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. 2004.
-
FSMB. Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office. FSMB Website. 2013.
-
McNicholas LF. Buprenorphine: Induction, Dosing and Related Issues. American Psychiatric Association Sponsored Webinar; 2011.
-
Kraus ML, Alford DP, Kotz MM, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction. J Addict Med. 2011;5(4):254-263.
-
Kosten TR, George TP. The neurobiology of opioid addiction: implications for treatment. NIDA Sci Pract Perspect. 2002;1(1):13-20.
-
Fiellin DA, Schottenfeld RS, Cutter CJ, et al. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial. JAMA Intern Med. 2014;174(12):1947-1954.
-
Weiss RD, Potter JS, Fiellin DA. Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence. Arch Gen Psychiatry. 2012;68(12):1238-1246.
-
FDA. FDA approves first buprenorphine implant for treatment of opioid dependence. FDA News Events. May 2016.
-
ASAM. The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use. June 2015.
-
Farmer CM, Lindsay D, Williams J, et al. Practice Guidelines for Burprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process. 2015;36(2).
-
Renner Britta, Kwon Sunkyo, Yang Byung-Hwan, et al. Social-Cognitive Predictors of Dietary Behaviors in South Korean Men and Women. Int J Behav Med. 2008;15(1):4-13. doi:10.1080/10705500701783785.
-
NIDA. Principles of drug addiction treatment: A research-based guide (Third Edition_. December 2012.
-
USDHHS. Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements. 2016.
-
Emrick CD. Alcoholics Anonymous and Other 12-Step Groups. Textb Subst Abuse Treat. 1999:403-411.
-
Finch JW, Kamien JB, Amass L. Two-year experience with buprenorphine-naloxone (Suboxone) for maintenance treatment of opioid dependence within a private practice setting. J Addict Med. 2014;1(2):104-110.
-
Mintzer IL, Eisenberg M, Terra M, et al. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med. 2007;5(2):146-150.
-
Soyka M. Buprenorphine and buprenorphine/naloxone intoxication in children — How strong is the risk?. Curr Drug Abuse Rev. 2013;6(1):63-70.
-
Drug Enforcement Administration (DEA). Buprenorphine. 2013.
-
SAMHSA Press Office. Sharp rise in buprenorphine-related emergency department visits from 2005 to 2010. 2013.
-
Martin T, Rocque M. Accidental and Non-Accidental Ingestion of Methadone and Buprenorphine in Childhood: A Single Center Experience, 1999-2009. Curr Drug Saf. 2009;6:12-16.
-
Indivior Inc. Suboxone Highlights of Prescribing Information. http://www.suboxone.com/. December 2016.
-
Food and Drug Administration (FDA). Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) Risk Evaluation and Mitigation Strategy (REMS). 2013.
-
FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. US Food Drug Adm Cent Drug Eval Res. August 2016.
-
FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. US Food Drug Adm Cent Drug Eval Res. September 2017.
-
Wartenberg A. Management of Buprenorphine Side Effects. 2013.
-
RxList. Oxazepam (Oxazepam Tablets): Side Effects, Interactions, Warning, Dosage & Uses. RxList. 2017.
-
RxList. Ativan (Lorazepam): Side Effects, Interactions, Warning, Dosage & Uses. RxList. 2017.
-
RxList. Diazepam (Diazepam Tablets): Side Effects, Interactions, Warning, Dosage & Uses. RxList. 2017.
-
Drugs.com. Naloxone. Drugs.com. 2015.
-
Irwin RS, Rippe JM. Irwin and Rippe’s Intensive Care Medicine. Lippincott Williams & Wilkins; 2012.
-
BMJ. Benzodiazepine overdose. 2017.
-
Substance Abuse and Mental Health Services Administration (SAMHSA). About Buprenorphine Therapy. 2011.
-
SAMHSA. SAMHSA opioid overdose prevention toolkit. 2014.
-
Morasco BJ, Cavanagh R, Gritzner S, et al. Care management practices for chronic pain in veterans prescribed high doses of opioid medications. Farm Pract. 2013;6:671-678.
-
Jones HE, Fischer G, Heil SH. Maternal Opioid Treatment: Human Experimental Research (MOTHER) – approach, issues and lessons learned. Addiction. 2012;107:28-35.
-
Daitch D, Daitch J, Novinson D, et al. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Pain Med. 2014;15(12):2087-2094.
-
Waknine Y. FDA Approves 7-Day Buprenorphine Pain Patch. 2010.
-
FDA. Medication Guide: ButransTM CIII (buprenorphine) Transdermal System. 2010.
-
Purdue Pharma. ButransTM CIII (buprenorphine) Transdermal System. Butrans Website. 2010.
-
Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. SupportiveOncology.net. 2012.
-
Fiellin D. Treatment of acute pain in patients receiving buprenorphine/naloxone. March 2014.
-
Alford DP, Labelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425-431.
-
Alford DP, Compton P, Samet JH. Acute Pain Management for Patients Receiving Maintenance Methadone or Buprenorphine Therapy. Ann Intern Med. 2006;144(2):127-134.
-
Stephenson DK, SAM Committee on Treatment of Opioid Dependence. Draft Guidelines for Physicians Working in California Opioid Treatment Programs. 2008.
-
Weiss Roger D, Potter Jennifer S, Copersino Marc L, et al. Conducting Clinical Research with Prescription Opioid Dependence: Defining the Population. Am J Addict. 2010;19(2):141-146. doi:10.1111/j.1521-0391.2009.00017.x.
-
Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders Stabilization Pocket Card. 2015.
-
Melemis SM. Relapse prevention and the five rules of recovery. Yale J Biol Med. 2015;88:3.
-
Nielsen S, Hillhouse M, Thomas C. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. J Addict Med. 2013;7(1):33-38.
-
Dunn KE, Sigmon SC, Strain EC. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. Drug Alcohol Depend. 2011;119(1-2):1-9.
-
SAMHSA/CSAT. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. 2004.
-
SAMHSA. Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update. Winter 2016.
-
ASAM. The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use. June 2015.
-
Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders Stabilization Pocket Card. 2015.
-
Jones HE. Treating opioid use disorders during pregnancy: historical, current, and future directions. Subst Abus. 2013;34(2):89-91.
-
Kraus ML, Alford DP, Kotz MM, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction. J Addict Med. 2011;5(4):254-263.
-
Food and Drug Administration (FDA). Buprenorphine Drug Label. 2010.
-
Jones HE, Fischer G, Heil SH. Maternal Opioid Treatment: Human Experimental Research (MOTHER) – approach, issues and lessons learned. Addiction. 2012;107:28-35.
-
McCarthy JJ, Leamon MH, Parr MS, et al. High-dose maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol. 2005;193(3 Pt 1):606-610.
-
Thomas CP, Fullerton CA, Kim M, et al. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014;65(2):158-170.
-
Sullivan M, Martin J (original author). New Information on Buprenorphine Treatment During Pregnancy. 2014.
-
Stanhope TJ, Gill LA, Rose C. Chronic opioid use during pregnancy: maternal and fetal implications. Clin Perinatol. 2013;40(3):337-350.
-
Martin J. PCSS-MAT Guidance: Pregnancy and buprenorphine treatment. Physicians’ Clinical Support System for Medication Assisted Treatment (PCSS-MAT). 2006.
-
Association of State and Territorial Health Officials (ASTHO). Neonatal Abstinence Syndrome: How States Can Help Advance the Knowledge Base for Primary Prevention and Best Practices of Care. 2014.
-
O’Connor AB, Collett A, Alto WA, et al. Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy. Journal of Midwifery Women’s Health. 2013;58(4):383-388.
-
Reckitt Benckiser Pharmaceuticals Inc. SUBOXONE (buprenorphine hydrochloride, naloxone hydrochloride) film, soluble [Reckitt Benckiser Pharmaceuticals Inc]. DailyMed. 2014.
-
Jones HE, Kaltenbach K, Heil SH, et al. Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure. N Engl J Med. 2010;363:2320-2331.
-
Matson SC, Hobson G, Abdel-Rasoul M, et al. A Retrospective Study of Retention of Opioid-Dependent Adolescents and Young Adults in an Outpatient Buprenorphine/Naloxone Clinic. Addict Behav. 2014;8(3):176-182.
-
Levy S, Vaughan BL, Angulo M, et al. Buprenorphine replacement therapy for adolescents with opioid dependence: early experience from a children’s hospital-based outpatient treatment program. J Adolesc Health. 2007;40(5):477-482.
-
Minozzi S, Amato L, Davoli M. Maintenance treatments for opiate dependent adolescent. Cochrane Database Syst Rev. 2009;15(2):CD007210.
-
Subramaniam GA, Fishman MJ, Woody G. Treatment of opioid-dependent adolescents and young adults with buprenorphine. Curr Psychiatry Rep. 2009;11(5):360-363.
-
Woody G, Poole S, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trail. AMA. 2008;300(17):2003-2011.
-
Stewart DG, Brown SA. Withdrawal and dependency symptoms among adolescent alcohol and drug abusers. Addiction. 1995;90(5):627-635.
-
Ling W, Hillhouse M, Domier C, et al. Buprenorphine tapering schedule and illicit opioid use. Addiction. 2009;104(2):256-265.
-
SAMHSA. An Introduction to Extended-Release Injectable Naltrexone for the Treatment of People With Opioid Dependence. SAMHSA Advis. 2012;HHS Publication No. (SMA) 12-4682:1-8.
-
Subramaniam G, Levy S. PCSS-MAT Guidance: Treatment of opioid dependent adolescents and young adults using sublingual buprenorphine. 2010.
-
SAMHSA. Treatment of Adolescents With Substance Use Disorders. Treatment Improvement Protocol Series, No. 32. Rockville, Md: Center For Substance Abuse Treatment; 1999.
-
Hopfer CJ, Khuri E, Crowley TJ, et al. Adolescent heroin use: a review of the descriptive and treatment literature. J Subst Abuse Treat. 2002;23(3):231-237.
-
Blow FC. Special issues in treatment: old adults. In: In: Graham AW, Schultz TK, May-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine. Vol 3rd edition. Chevy Chase, Md: American Society of Addiction Medicine; 2003.
-
Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. ; 2014.
-
Ling W. Prescription Drug Abuse. Western Conference on Addiction. November 13, 2005. Universal City, CA.
-
Alford DP, Labelle CT, Richardson JM, et al. Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-Based Setting. Soc Gen Intern Med. 2007;22:171-176.
-
NCCHC. Substance Use Disorder Treatment for Adults and Adolescents. October 2016.
-
Renner J, Saxon A, Levounis P. Buprenorphine Update and Evolving Standards of Care. IPS: The Mental Health Services Conference. October 2015. New York City.
-
Öhlin L, Fridell M, Nyhlén A. Buprenorphine maintenance program with contracted work/education and low tolerance for non-prescribed drug use: a cohort study of outcome for women and men after seven years. BMC Psychiatry. March 24, 2015;15(56).
-
FSMB. Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office. FSMB Website. 2013.
-
SAMHSA. Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update. Winter 2016.
-
McNicholas LF. Buprenorphine: Induction, Dosing and Related Issues. American Psychiatric Association Sponsored Webinar. 2011.
-
FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. US Food Drug Adm Cent Drug Eval Res. September 20, 2017.
-
Martin J. Adherence, Diversion and Misuse of Sublingual Buprenorphine. updated 2014 2009.
-
Monte AA, Mandell T, Wilford BB, et al. Diversion of Buprenorphine/Naloxone Coformulated Tablets in a Region with High Prescribing Prevalence. J of Addictive Diseases. 2009;28:226-231.
-
Johanson CE, Arfken CL, DiMenza S, et al. Diversion and Abuse of Buprenorphine: Findings from National Surveys of Treatment Patients and Physicians. Drug Alcohol Depend. 2012;120(1-3):190-195.
-
Dart R. Evaluation of ADFs Using RADARS System Data. 2011.
-
Dasgupta N. RADARS System Subutex & Suboxone: How Much is Prescribed vs. Abuse/Diversion Reports. SAMHSA Meeting on Buprenorphine. 2010.
-
Lofwall M. Minimizing the Risks of Buprenorphine Diversion and Misuse from Office-Based Treatment. 2011.
-
Lavonas EJ, Banner W, Bradt P, et al. Root Causes, Clinical Effects, and Outcomes of Unintentional Exposures to Buprenorphine by Young Children. J Pediatr. 2013;163(5):1377-1383.
-
Clinical Tools, Inc. Motivational Interviewing: Managing Challenging Patient Behavior – YouTube. September 15, 2016.
-
Christo PJ, Manchikanti L, Ruan X, et al. Urine Drug Testing In Chronic Pain. Pain Physician. 2011;14:123-143.
-
Gourlay D. Urine Drug Testing in Chronic Pain: A Patient Centered Approach (AMA) [webinar]. 2013.
-
Gourlay D, Heit HA, Caplan YH. Urine Drug Testing in Clinical Practice: The Art and Science of Patient Care. Johns Hopkins Med. 2012;5.
-
Heit HA, Gourlay DL. Urine Drug Testing in Pain Medicine. J Pain Symptom Manage. 2004;27:260-267.
-
Department of Health and Human Services (DHHS). Mandatory Guidelines for Federal Workplace Drug Testing Programs. Fed Regist. 2008;73(228):71858-71907.
-
SAMHSA/CSAT. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. 2004.
-
SAMSHA. Treatment Episode Data Set (TEDS): 2000-2010. National Admissions to Substance Abuse Treatment Services. 2012.
-
CADCA. Comprehensive Addiction and Recovery Act (CARA). CADCA.org. 2016.
-
Walden Greg. Text – H.R.6 – 115th Congress (2017-2018): SUPPORT for Patients and Communities Act. October 2018.
-
SAMSHA. National Survey of Substance Abuse Treatment Services (N-SSATS): 2014. ; 2016.
-
Alford DP, Labelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425-431.
-
Pade PA, Cardon KE, Hoffman RM, et al. Prescription opioid abuse, chronic pain, and primary care: a Co-occurring Disorders Clinic in the chronic disease model. J Subst Abuse Treat. 2012;43(4):446-450.
-
Kahan M, Srivastava A, Ordean A, et al. Buprenorphine: new treatment of opioid addiction in primary care. Can Fam Physician. 2011;57(3):281-289.
-
FSMB. Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office. FSMB Website. 2013.
-
ASAM. Summary of the Comprehensive Addiction and Recovery Act. 2016.
-
SAMHSA/CSAT. Confidentiality of Patient Records for Alcohol and Other Drug Treatment. Rockville, Md: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration; 1994.
-
SAMHSA. Substance Abuse Confidentiality Regulations. 2015.
-
SAMHSA/CSAT. Treatment for Alcohol and Other Drug Abuse: Opportunities for Coordination. Rockville, Md: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration; 1994.
-
SAMHSA/CSAT. Intensive Outpatient Treatment for Alcohol and Other Drug Abuse. Rockville, Md: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration; 1994.
-
Gallagher C. What Waivered Physicans Need to Understand About DEA Requirements. 2010.
-
Drug Enforcement Administration, Justice. § 1301.75 Physical security controls for practitioners. 2005.
-
Drug Enforcement Administration. Code of Federal Regulations: Section 1304.03 Maintenance of records and inventories. 2000.
-
US Department of Justice. Title 21 Code of Federal Regulations: PART 1311 —REQUIREMENTS FOR ELECTRONIC ORDERS AND PRESCRIPTIONS. 2010.
-
Lowes R. e-Prescribing Controlled Substances Now Legal Nationwide. MedScape. 2015.
-
Salsitz EA, Wunsch MJ. PCSS-B Guidance on Drug Enforcement Administration Requirements for Prescribers and Dispensers of Buprenorphine and Buprenorphine/Naloxone. 2010.
-
Renner J, Saxon A, Levounis P. Buprenorphine Update and Evolving Standards of Care. IPS: The Mental Health Services Conference. October 2015. New York City.
-
HHS. HHS announces new actions to combat opioid epidemic. HHS.gov. July 2016.
-
USDHHS. Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements. 2016.
-
Stanton A, McLoed C, Luckey B, et al. SAMHSA/CSAT Evaluation of the Buprenorphine Waiver Program. 37th Annual Medical- Scientific Conference of the American Society of Addiction Medicine. 2006.
-
Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014;8(5):315-326.
-
SAMHSA. Physician and Program Data. SAMHSA.gov. 2018.
-
U.S. Census Bureau. 2012 Statistical Abstract of the United States. Census.gov. 2012.
-
SAMHSA. Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. SAMHSA.gov. 2017.
-
Roche AM, Freeman T. Brief Interventions: Good in Theory but Weak in Practice Drug Alcohol Rev. 2004;23(1):11-18. doi:10.1080/09595230410001645510.
-
D’Amico EJ, Paddock SM, Burnam A, Kung F-Y. Identification of and Guidance for Problem Drinking by General Medical Providers: Results from a National Survey Med Care. 2005;43(3):229-236.
-
Miller W, Rollnick S. Motivational Interviewing: Helping People Change. Vol 3rd ed. New York: Guilford Press; 2012. http://www.guilford.com/books/Motivational-Interviewing/Miller-Rollnick/9781609182274. Accessed July 8, 2014.
-
Rahm A, Boggs J, Martin C, et al. Facilitators and barriers to implementing SBIRT in primary care in integrated health care settings. Substance Abuse. 2015;36(3):281-288. https://www.ncbi.nlm.nih.gov/pubmed/25127073. Accessed May 27, 2015.
-
VanBuskirk KA, Wetherell JL. Motivational Interviewing Used in Primary Care A Systematic Review and Meta-analysis. J Behav Med. 2014;37(4):768-780. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118674/. Accessed June 11, 2019 doi:10.1007/s10865-013-9527-4.
-
Midboe AM, Cucciare MA, Trafton JA, Ketroser N, Chardos JF. Implementing motivational interviewing in primary care: the role of provider characteristics. Transl Behav Med. 2011;1(4):588-594. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717678/. Accessed March 27, 2019 doi:10.1007/s13142-011-0080-9.
-
Saitz R. Addressing Unhealthy Alcohol Use in Primary Care. Springer; 2013. https://www.amazon.com/Addressing-Unhealthy-Alcohol-Primary-Care/dp/146144778X. Accessed July 27, 2017.
-
BSAS. SBIRT: A Step-By-Step Guide. 2012. http://www.masbirt.org/sites/www.masbirt.org/files/documents/toolkit.pdf. Accessed March 19, 2015.
-
Le Berre A, Vabret F, Cauvin C, et al. Cognitive barriers to readiness to change in alcohol-dependent patients. Alcoholism: Clinical and Experimental Research. 2012;36:1542-1549. http://www.ncbi.nlm.nih.gov/pubmed/22458335. Accessed June 18, 2015.
-
Resnicow K, McMaster F. Motivational Interviewing: moving from why to how with autonomy support. Int J Behav Nutr Phys Act. 2012;9:19. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330017/. Accessed March 19, 2015.
-
Harmon-Jones E, Gable P, Price T. The influence of affective states varying in motivational intensity on cognitive scope. Front Integr Neurosci. 2012;6. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437552/. Accessed April 23, 2015.
-
Moyers T. The relationship in motivational interviewing. Psychotherapy. 2014;51(3):358-363. http://psycnet.apa.org/journals/pst/51/3/358. Accessed March 19, 2015 doi:http://dx.doi.org/10.1037/a0036910.
-
Norcross J, Krebs P, Prochaska J. Stages of change. Journal of Clinical Psychology. 2011;67:143-154. http://www.ncbi.nlm.nih.gov/pubmed/21157930. Accessed June 18, 2015.
-
SAMHSA. Enhancing Motivation For Change in Substance Abuse Treatment. January 2013. https://store.samhsa.gov/product/TIP-35-Enhancing-Motivation-for-Change-in-Substance-Abuse-Treatment/SMA13-4212. Accessed March 19, 2015.
-
Westra H, Aviram A. Core skills in motivational interviewing. Psychotherapy. 2013;50(3):278-8. https://www.ncbi.nlm.nih.gov/pubmed/24000834. Accessed March 19, 2015.
-
Ager R, Roahen-Harrison S, Toriello P, et al. Predictors of adopting motivational enhancement therapy. Research on Social Work Practice. 2011;21:65-76. http://rsw.sagepub.com/content/early/2010/01/20/1049731509353170. Accessed June 16, 2015.
-
NIDA. Motivational enhancement therapy (alcohol, marijuana, nicotine). NIDA. 2012. http://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/evidence-based-approaches-to-drug-addiction-treatment/behavioral-2. Accessed June 17, 2015.
-
Dieperink E, Fuller B, Isenhart C, et al. Efficacy of motivational enhancement therapy on alcohol use disorders in patients with chronic hepatitis C: a randomized controlled trial. Addiction. 2014;109:1869-1877. http://www.ncbi.nlm.nih.gov/pubmed/25040898. Accessed March 25, 2015.
-
CDC. Planning and Implementing Screening and Brief Intervention for Risky Alcohol Use: A Step-by-Sep Guide for Primary Care Practices. 2014. https://www.cdc.gov/ncbddd/fasd/documents/AlcoholSBIImplementationGuide.pdf. Accessed August 17, 2017.
-
Fishbain D, Cole B, Lewis J, et al. What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review Pain Medicine. 2008;9(4):444-459.
-
Chou R, Fanciullo G, Fine P, Miaskowski C, Passik S, Portenoy R. Opioids for Chronic Noncancer Pain: Prediction and Identification of Aberrant Drug-Related Behaviors: A Review of Evidence for an American Pain Society and American Academy of Pain Medicine Clinical Practice Guideline J Pain. 2009;10(2):131-146.
-
CASA Columbia. Under the counter: the diversion and abuse of controlled prescription drugs in the U.S.. Columbia; 2005. http://www.casacolumbia.org/addiction-research/reports/under-the-counter-diversion-abuse-controlled-perscription-drugs. Accessed April 1, 2015.
-
Heit H. Aberrant behaviors – refer or triage. Emerging Solutions in Pain Website. 2009. http://www.emergingsolutionsinpain.com/87-resources/newsletter/243-the-beacon-newsletter-volume-i-issue-2#askexpert. Accessed October 23, 2013.
-
VA/DoD. Clinical Practice Guideline for the Management of Opioid Therapy for Chronic Pain. 2010. https://www.va.gov/painmanagement/docs/cpg_opioidtherapy_summary.pdf. Accessed April 28, 2014.
-
FSMB. Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office. FSMB Website. 2013. https://www.fsmb.org/Media/Default/PDF/FSMB/Advocacy/2013_model_policy_treatment_opioid_addiction.pdf. Accessed October 11, 2013.
-
Passik S, Kirsh K, Webster L. Pseudoaddiction Revisited: A Commentary on Clinical and Historical Considerations Pain Management. 2011;1(3):239-248.
-
NAABT. Physical Dependence and Addiction An Important Distinction. The National Alliance of Advocates for Buprenorphine Treatment. 2014. http://www.naabt.org/addiction_physical-dependence.cfm. Accessed July 1, 2015.
-
Schnoll S, Finch J. Medical Education for Pain and Addiction: Making Progress Toward Answering a Need. The Journal of Law, Medicine & Ethics. 1994. http://onlinelibrary.wiley.com/doi/10.1111/j.1748-720X.1994.tb01303.x/abstract. Accessed October 23, 2013.
-
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Vol 5th edition. Washington, DC: Author; 2013. https://www.amazon.com/Diagnostic-Statistical-Manual-Mental-Disorders/dp/0890425558/ref=sr_1_1?s=books&ie=UTF8&qid=1492003452&sr=1-1&keywords=dsm+5. Accessed August 10, 2013.
-
Substance Abuse and Mental Health Services Administration (US), Office of the Surgeon General (US). Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health. Washington (DC): US Department of Health and Human Services; 2016. http://www.ncbi.nlm.nih.gov/books/NBK424857/. Accessed November 17, 2016.
-
Chou R, Fanciullo GJ, Fine PG, et al. Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain J Pain. 2009;10(2):113-130. doi:10.1016/j.jpain.2008.10.008.
-
Butler S, Budman S, Fernandez K, et al. Development and Validation of the Current Opioid Misuse Measure Pain. 2007;130(1-2):144-156.
-
Compton P, Darakjian J, Miotto K. Screening for Addiction in Patients with Chronic Pain and “Problematic” Substance Use: Evaluation of a Pilot Assessment Tool J Pain Symptom Manage. 1998;16(6):355-363.
-
Compton P, Wu S, Schieffer B, et al. Introduction to a Self-Report Version of the Prescription Drug Use Questionnaire and Relationship to Medication Agreement Noncompliance J Pain Symptom Manage. 2008;36(4):383-395.
-
Adams L, Gatchel R, Robinson R, et al. Development of a Self-Report Screening Instrument for Assessing Potential Opioid Medication Misuse in Chronic Pain Patients J Pain Symptom Manage. 2004;27:440-459.
-
Peppin J, Passik S, Couto J, et al. Recommendations for Urine Drug Monitoring as a Component of Opioid Therapy in the Treatment of Chronic Pain Pain Medicine. 2012;13(7):886-896.
-
Chou R, Fanciullo GJ, Fine PG, et al. Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain J Pain. 2009;10(2):113-130. doi:10.1016/j.jpain.2008.10.008.
-
Dowell D, Haegerich T, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016 MMWR Recomm Rep. 2016;65(1):1-49. doi:10.15585/mmwr.rr6501e1er.
-
Couto J, Romney M, Leider H, et al. High Rates of Inappropriate Drug Use in the Chronic Pain Population Population Health Management. 2009;12(4):185-190.
-
Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2012 national survey on drug use and health: summary of national findings. U.S. Department of Health and Human Services; 2013. http://archive.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/NationalFindings/NSDUHresults2012.htm. Accessed April 1, 2015.
-
CASA Columbia. Under the counter: the diversion and abuse of controlled prescription drugs in the U.S.. Columbia; 2005. http://www.casacolumbia.org/addiction-research/reports/under-the-counter-diversion-abuse-controlled-perscription-drugs. Accessed April 1, 2015.
-
Adams N, Plane M, Fleming M, et al. Opioids and the Treatment of Chronic Pain in a Primary Care Sample J Pain Symptom Manage. 2001;21:791-796.
-
Hall A, Logan J, Toblin R, et al. Patterns of Abuse Among Unintentional Pharmaceutical Overdose Fatalities JAMA. 2008;300(22):2613-2620.
-
Dart R. Opioid Abuse, Misuse, and Diversion: Strategies for Prevention. Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS)American Academy of Pain Medicine Meeting. 2009.
-
Simeone R. Doctor shopping behavior and the diversion of opioid analgesics: 2008-2012. 2014. http://www.pdmpassist.org/pdf/Opioid_Diversion_08142014.pdf. Accessed July 6, 2015.
-
Center for Medicare & Medicaid Services. What is a prescriber’s role in preventing the diversion of prescription drugs?. 2014. https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Provider-Education-Toolkits/Downloads/prescriberrole-drugdiversion-factsheet-082914.pdf. Accessed July 6, 2015.
-
Cicero J, Dart R, Inciardi J, et al. The Development of a Comprehensive Risk-Management Program for Prescription Opioid Analgesics: Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) Pain Medicine. 2007;8(2):157-169.
-
Inciardi J, Surratt H, Cicero T, et al. Prescription Opioid Abuse and Diversion in an Urban Community: The Results of an Ultra-Rapid Assessment Pain Med. 2009;10(3):537-548.
-
Merrick M. Prescription Opioids and Overdose Deaths JAMA. 2009;301(17):1767.
-
National Drug Intelligence Center. Heroin Distribution in Three Cities: New York, Chicago, and Los Angeles. Johnstown, Pa: U.S. Dept. of Justice, National Drug Intelligence Center; 2000a. http://www.worldcat.org/title/heroin-distribution-in-three-cities-new-york-chicago-and-los-angeles/oclc/53077929. .
-
Office of National Drug Control Policy. Pulse Check: trends in drug abuse, January-June 2002 reporting period. 2002. https://www.ncjrs.gov/ondcppubs/publications/drugfact/pulsechk/pulse_nov02.pdf. Accessed January 31, 2006.
-
Stephens R. The Street Addict Role: A Theory of Heroin Addiction. Albany: State University of New York Press; 1991. https://www.amazon.com/dp/0791406202. Accessed October 23, 2013.
-
SAMHSA, CSAT. OxyContin®: Prescription Drug Abuse b 2001.
-
Drug Abuse Warning Network (DAWN). Highlights of the 2011 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. The Dawn Report; 2013:127. https://www.samhsa.gov/data/sites/default/files/DAWN127/DAWN127/sr127-DAWN-highlights.htm. Accessed October 10, 2013.
-
U.S. Department of Justice, Drug Enforcement Administration. Dispensing Controlled Substances for the Treatment of Pain Federal Register Notices. 2006;71(172):52715-52723.
-
Walker M, Webster L. Risk Factors for Drug Diversion in a Pain Clinic Patient Population Journal of Opioid Management. 2012;8(6):351-362.
-
Drug and Alcohol Services Information System. Characteristics of Primary Prescription and OTC Treatment Admissions: 2002. 2004. http://www.dhs.state.il.us/page.aspx?item=4841. Accessed October 31, 2014.
-
Cole B. Recognizing Preventing and Medication Diversion: Don’t Let Diversion of Pain Medication Hamper Your Ability to Treat Chronic Pain Family Practice Management. 2001;8(2):37-41.
-
VA/DoD. Clinical Practice Guideline for the Management of Opioid Therapy for Chronic Pain 2003.
-
SAMHSA. Managing chronic pain in adults with or in recovery from substance use disorders. Treatment Improvement Protocol (TIP) Series, No. 54; 2012. https://www.ncbi.nlm.nih.gov/books/NBK92046/#_ch4_s15. Accessed July 8, 2015.
-
ACPM. Use, abuse, misuse, and disposal of prescription pain medication clinical reference. 2011. https://c.ymcdn.com/sites/www.acpm.org/resource/resmgr/timetools-files/painmedsclinicalreference.pdf. Accessed July 7, 2015.
-
FSMB. Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office. FSMB Website. 2013. https://www.fsmb.org/Media/Default/PDF/FSMB/Advocacy/2013_model_policy_treatment_opioid_addiction.pdf. Accessed October 11, 2013.
-
Drug Enforcement Administration. State Prescription Drug Monitoring Programs. 2011. http://www.deadiversion.usdoj.gov/faq/rx_monitor.htm. .
-
Hooten W, Timming R, Belgrade M, et al. Assessment and management of chronic pain. 2013. https://www.azprioritycare.com/Content/providers/2014-ChronicPain-ICSI.PDF. Accessed July 1, 2015.
-
VAHPC. Risk evaluation & mitigation tool-kit: strategies to promote the safe use of opioids. 2012. https://c.ymcdn.com/sites/vah.site-ym.com/resource/resmgr/REM_Folder/Final_REM_Tool_Kit_for_elect.pdf. Accessed July 7, 2015.
-
Office o f National Drug Control Policy. Proper Disposal of Prescription Drugs. October 2009. http://projectdrugdrop.org/wp-content/uploads/Documents/proper.disposal.gov.pdf. Accessed August 15, 2018.
-
Taylor R, Raffa R, Pergolizzi J. Opioid Formulations with Sequestered Naltrexone: A Perspective Review Ther Adv Drug Saf. 2014;5(3):129-137.
-
Center for Drug Evaluation and Research. Abuse-deterrent opioids – evaluation and labeling. 2015. https://www.fda.gov/downloads/Drugs/Guidances/UCM334743.pdf. Accessed July 7, 2015.
-
NDIC. Methadone Diversion, Abuse, and Misuse: Deaths Increasing at Alarming Rate. 2010. https://www.justice.gov/archive/ndic/pubs25/25930/25930p.pdf. .
-
Dart R. Evaluation of ADFs Using RADARS System Data. 2011. http://www.thblack.com/links/RSD/RADARS(R)%20System_2011%20Annual%20Meeting%20Summary.pdf. Accessed April 30, 2013.
-
Dasgupta N. RADARS System Subutex & Suboxone: How Much is Prescribed vs. Abuse/Diversion Reports. SAMHSA Meeting on Buprenorphine. 2010. https://www.radars.org/system/publications/2008_Dasgupta_CSAT.pdf. Accessed April 30, 2013.
-
Fishman SM, Papazian JS, Gonzalez S, Riches PS, Gilson A. Regulating Opioid Prescribing Through Prescription Monitoring Programs: Balancing Drug Diversion and Treatment of Pain Pain Medicine. 2004;5(3):309-324.
-
Katz N, Adams E, Benneyan J, et al. Foundations of Opioid Risk Management Clinical Journal of Pain. 2007;23(2):103-118.
-
Passik S. Issues in Long-Term Opioid Therapy: Unmet Needs, Risks, and Solutions Mayo Clin Proc. 2009;84(7):593-601.
-
Drug Enforcement Administration. State Prescription Drug Monitoring Programs: Questions & Answers. US Department of Justice. 2008. https://www.deadiversion.usdoj.gov/faq/rx_monitor.htm. Accessed June 24, 2009.
-
Green T, Mann M, Bowman S, et al. How Does Use of a Prescription Monitoring Program Change Medical Practice? Pain Medicine. 2012;13(10):1314-1323.
-
Wang J, Christo P. The Influence of Prescription Monitoring Programs on Chronic Pain Management Pain Physician. 2009;12:507-515.
-
Brushwood D. Electronic Prescription Monitoring Programs: A Data-Reporting Tool Designed to Prevent Drug Diversion 2007.
-
Eccher D. Maine’s Prescription Monitoring Program: Preventing Prescription Drug Misuse. 2009. https://www.maine.gov/dhhs/samhs/osa/data/pmp/. Accessed June 25, 2009.
-
Dowell D, Kunins H, Farley T. Opioid Analgesics – Risky Drugs, Not Risky Patients JAMA. 2013;309(21):2219-2220.
-
Rudd RA. Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65. http://www.cdc.gov/mmwr/volumes/65/wr/mm655051e1.htm. Accessed December 20, 2016 doi:10.15585/mmwr.mm655051e1.
-
Warner M, Chen L, Makuc D. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. 2009. http://www.cdc.gov/nchs/data/databriefs/db22.pdf. Accessed April 15, 2011.
-
Drug Abuse Warning Network. Highlights of the 2009 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits. 2010. https://www.hsdl.org/?abstract&did=7883. Accessed January 11, 2011.
-
Webster L, Fine P. Overdose Deaths Demand a New Paradigm for Opioid Rotation Pain Medicine. 2012;13(4):571-574.
-
Coolen P. Overdose Deaths Involving Prescription Opioids among Medicaid Enrollees— Washington, 2004-2007 CDC: Morbidity Mortality Weekly Report. 2009;58(42):1171-1175.
-
FDA. FDA approves injectable drug to treat opioid-dependent patients. ; 2010. http://web.archive.org/web/20101013020143/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229109.htm. Accessed October 8, 2018.
-
Stein D, Isper J, Seedat S. Pharmacotherapy for Post Traumatic Stress Disorder (PTSD) Cochrane Database Systematic Reviews. 2006;1:CD002795.
-
Taylor F, Martin P, Thompson C, et al. Prazosin Effects on Objective Sleep Measures and Clinical Symptoms in Civilian Trauma Posttraumatic Stress Disorder: A Placebo-Controlled Study Biological Psychiatry. 2008;63(6):629-632.
-
Harned M, Sloan P. Safety Concerns with Long-Term Opioid Use Expert Opin Drug Saf. 2016;15(7):955-962.
-
Dunn K, Saunders K, Rutter C, et al. Opioid Prescriptions for Chronic Pain and Overdose: A Cohort Study Annals of Internal Medicine. 2010;152(2):85-92.
-
Fitzgibbon D, Rathmell J, Michna E, et al. Malpractice Claims Associated with Medication Management for Chronic Pain Anesthesiology. 2010;112(4):777-778.
-
Eggleston W, Clark K, Marraffa J. Loperamide abuse associated with cardiac dysrhythmia and death. Annals of Emergency Medicine. 2016. http://www.annemergmed.com/article/S0196-0644(16)30052-X/fulltext. Accessed May 4, 2016 doi:http://dx.doi.org/10.1016/j.annemergmed.2016.03.047.
-
Fine P. Opioid Rotation J Pain Symptom Management. 2009;38(3):418-425.
-
Vissers K, Besse K, Hans G, et al. Opioid Rotation in the Management of Chronic Pain: Where Is the Evidence? Pain Practice. 2010;10(2):85-93.
-
Fingerhut L. Increases in poisoning and methadone-related deaths: United States, 1999-2005. 2008. https://www.cdc.gov/nchs/data/hestat/poisoning/poisoning.pdf. Accessed March 5, 2010.
-
DEA. Automation of Reports and Consolidated Orders System (ARCOS). 2009. https://www.deadiversion.usdoj.gov/arcos/index.html. Accessed December 7, 2009.
-
Hall A, Paulozzi L. Prescription Opioids and Overdose Deaths—Reply JAMA. 2009;301(17):1767-1768.
-
VA/DoD. Clinical Practice Guideline for the Management of Opioid Therapy for Chronic Pain. 2010. https://www.va.gov/painmanagement/docs/cpg_opioidtherapy_summary.pdf. Accessed April 28, 2014.
-
Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2012 national survey on drug use and health: summary of national findings. U.S. Department of Health and Human Services; 2013. http://archive.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/NationalFindings/NSDUHresults2012.htm. Accessed April 1, 2015.
-
Dowell D, Haegerich T, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016 MMWR Recomm Rep. 2016;65(1):1-49. doi:10.15585/mmwr.rr6501e1er.
-
Chou R, Fanciullo G, Fine P, et al. Clinical Guidelines for the Use of Chronic Opioid Therapy for Chronic Non-Cancer Pain J of Pain. 2009;10(2):113-130.
-
Gourlay D, Heit H. Universal Precautions Revisited: Managing the Inherited Pain Patient Pain Medicine.
-
CASA Columbia. Under the counter: the diversion and abuse of controlled prescription drugs in the U.S.. Columbia; 2005. http://www.casacolumbia.org/addiction-research/reports/under-the-counter-diversion-abuse-controlled-perscription-drugs. Accessed April 1, 2015.
-
Walden G. Text – H.R.6 – 115th Congress (2017-2018): SUPPORT for Patients and Communities Act. October 2018. https://www.congress.gov/bill/115th-congress/house-bill/6/text. Accessed October 8, 2018.
-
American Pain Society in conjunction with the American Academy of Pain Medicine. Guideline for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. Evidence Review. 2009. http://americanpainsociety.org/uploads/education/guidelines/chronic-opioid-therapy-cncp.pdf. Accessed September 7, 2010.
-
Savage S, Kirsh K, Passik S. Challenges in Using Opioids to Treat Pain in Persons with Substance Use Disorders Addiction Science & Clinical Practice. 2008;4(2):4-25.
-
Webster L, Dove B. Avoiding opioid abuse while managing pain. A guide for practitioners. Vol 1st ed. North Branch, MN: Sunrise River Press; 2007. http://www.amazon.com/dp/0962481483. Accessed October 23, 2013.
-
Miller WR, Rollnick S. Motivational Interviewing: Helping People Change, 3rd Edition Vol 3rd edition. New York, NY: The Guilford Press; 2012.
-
FSMB. Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office. FSMB Website. 2013. https://www.fsmb.org/Media/Default/PDF/FSMB/Advocacy/2013_model_policy_treatment_opioid_addiction.pdf. Accessed October 11, 2013.
-
Jamison RN, Ross EL, Michna E, Chen LQ, Holcomb C, Wasan AD. Substance Misuse Treatment for High-Risk Chronic Pain Patients on Opioid Therapy: A Randomized Trial Pain. 2010;150(3):390-400.
-
Hooten W, Timming R, Belgrade M, et al. Assessment and management of chronic pain. 2013. https://www.azprioritycare.com/Content/providers/2014-ChronicPain-ICSI.PDF. Accessed July 1, 2015.
-
Savage S. Management of Opioid Medications in Patients with Chronic Pain and Risk of Substance Abuse Current Psychiatry Reports. 2009;11:377-384.
-
Ziegler P. Addiction and the Treatment of Pain Substance Use and Misuse. 2005;40(1):1945-1954.
-
DEA. Schedules of Controlled Substances: Placement of Tramadol Into Schedule IV. DEA Office of Diversion Control Website. 2014. https://www.deadiversion.usdoj.gov/fed_regs/rules/2014/fr0702.htm. Accessed August 7, 2014.
-
Passik S, Kirsh K. Opioid Therapy in Patients with a History of Substance Abuse CNS Drugs. 2004;18(1):13-25.
-
VA/DoD. Clinical Practice Guideline for the Management of Opioid Therapy for Chronic Pain. 2010. https://www.va.gov/painmanagement/docs/cpg_opioidtherapy_summary.pdf. Accessed April 28, 2014.
-
Substance Abuse and Mental Health Services Administration, Office of Applied Studies. The TEDS Report: Substance Abuse Treatment Admissions Involving Abuse of Pain Relievers: 1998 and 2008. 2010. http://oas.samhsa.gov/2k10/230/230PainRelvr2k10Web.pdf. Accessed July 23, 2010.
-
Alford D, Compton P, Samet J. Acute Pain Management for Patients Receiving Maintenance Methadone or Buprenorphine Therapy Annals of Internal Medicine. 2006;144(2):127-134.
-
Waknine Y. FDA Approves 7-Day Buprenorphine Pain Patch. 2010. http://www.medscape.com/viewarticle/724626. Accessed July 13, 2011.
-
Heit H. Aberrant behaviors – refer or triage. Emerging Solutions in Pain Website. 2009. http://www.emergingsolutionsinpain.com/87-resources/newsletter/243-the-beacon-newsletter-volume-i-issue-2#askexpert. Accessed October 23, 2013.
-
Weaver M, Schnoll S. Opioid Treatment of Chronic Pain in Patients with Addiction Journal of Pain & Palliative Care Pharmacotherapy. 2002;16(3):2-26.
-
Menefee Pujol L, Katz N, Zacharoff K. The Role of Referral for Consultation in Pain Management 2009.
-
Compton P. Should Opioid Abusers Be Discharged from Opioid-Analgesic Therapy? Pain Medicine. 2008;9(4):383-390.
-
Meghani S, Wiedemer N, Becker W, et al. Predictors of Resolution of Aberrant Drug Behavior in Chronic Pain Patients Treated in a Structured Opioid Risk Management Program Pain Med. 2009;10(5):858-865.
-
Drug Enforcement Administration. Practitioner’s manual – an informational outline of the controlled substances act. DEA Office of Diversion Control Website. 2006. https://www.deadiversion.usdoj.gov/pubs/manuals/pract/pract_manual012508.pdf. Accessed July 6, 2015.
-
Solomon D, Furst D, Romain P. Patient education: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics). 2014. https://www.uptodate.com/contents/nonsteroidal-antiinflammatory-drugs-nsaids-beyond-the-basics?search=Nonsteroidal%20antiinflammatory%20drugs%20(NSAIDs)&source=search_result&selectedTitle=7~150&usage_type=default&display_rank=7. Accessed July 6, 2015.
-
Webster L. Misuse Emerging Solutions in Pain. 2010.
